Clinical investigation of therapeutic effects of sorafenib on cutaneous angiosarcoma

Clinical investigation of therapeutic effects of sorafenib on cutaneous angiosarcoma - Investigation of therapeutic effects of sorafenib on angiosarcoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017373

Enrollment

Registered

2015-05-07

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiosarcoma

Interventions

oral administration of sorafenib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Conventional therapy-resistant angiosarcoma

Exclusion criteria

Exclusion criteria: Possess the allergic reaction against sorafenib. Respilatory failure Interstitial pneumonia gastrointestinal hemorrhage cerebral hemorrhage

Design outcomes

Primary

Measure	Time frame
Antitumor effect	—

Countries

Japan

Contacts

Public ContactTaku Fujimura

Tohoku University Graduate School of Medicine Department of Dermatology

tfujimura1@med.tohoku.ac.jp022-717-7271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026